Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial

Sirwan Hadad, Takayuki Iwamoto, Lee Jordan, Colin Purdie, Susan Bray, Lee Baker, Gera Jellema, Steve Deharo, D. Grahame Hardie, Lajos Pusztai, Stacy Moulder-Thompson, John A. Dewar, Alastair M. Thompson

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot cohort of eight patients had core biopsy of the cancer at presentation, a week later (without treatment; internal control), then following metformin 500-mg o.d. for 1 week increased to 1-g b.d. for a further week continued to surgery. A further 47 patients had core biopsy at diagnosis were randomized to metformin (the same dose regimen) or no drug, and 2 weeks later had core biopsy at surgery. Ki67 immunohistochemistry, transcriptome analysis on formalin-fixed paraffin-embedded cores and serum insulin determination were performed blinded to treatment. Seven patients (7/32, 21.9%) receiving metformin withdrew because of gastrointestinal upset. The mean percentage of cells staining for Ki67 fell significantly following metformin treatment in both the pilot cohort (P = 0.041, paired t-test) and in the metformin arm (P = 0.027, Wilcoxon rank test) but was unchanged in the internal control or metformin control arms. Messenger RNA expression was significantly downregulated by metformin for PDE3B (phosphodiesterase 3B, cGMP-inhibited; a critical regulator of cAMP levels that affect activation of AMP-activated protein kinase, AMPK), confirmed by immunohistochemistry, SSR3, TP53 and CCDC14. By ingenuity pathway analysis, the tumour necrosis factor receptor 1 (TNFR1) signaling pathway was most affected by metformin: TGFB and MEKK were upregulated and cdc42 downregulated; mTOR and AMPK pathways were also affected. Gene set analysis additionally revealed that p53, BRCA1 and cell cycle pathways also had reduced expression following metformin. Mean serum insulin remained stable in patients receiving metformin but rose in control patients. This trial presents biomarker evidence for anti-proliferative effects of metformin in women with breast cancer and provides support for therapeutic trials of metformin.

Original languageEnglish
Pages (from-to)783-794
Number of pages12
JournalBreast Cancer Research and Treatment
Volume128
Issue number3
DOIs
Publication statusPublished - Aug 2011
Externally publishedYes

Fingerprint

Metformin
Breast Neoplasms
AMP-Activated Protein Kinases
Biopsy
Down-Regulation
Immunohistochemistry
Type 3 Cyclic Nucleotide Phosphodiesterases
Insulin
MAP Kinase Kinase Kinases
Tumor Necrosis Factor Receptors
Gene Expression Profiling
Therapeutics
Nonparametric Statistics
Serum
Paraffin
Formaldehyde

Keywords

  • Breast cancer
  • Clinical trial
  • ki67
  • Metformin
  • Transcriptome analyses

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evidence for biological effects of metformin in operable breast cancer : A pre-operative, window-of-opportunity, randomized trial. / Hadad, Sirwan; Iwamoto, Takayuki; Jordan, Lee; Purdie, Colin; Bray, Susan; Baker, Lee; Jellema, Gera; Deharo, Steve; Hardie, D. Grahame; Pusztai, Lajos; Moulder-Thompson, Stacy; Dewar, John A.; Thompson, Alastair M.

In: Breast Cancer Research and Treatment, Vol. 128, No. 3, 08.2011, p. 783-794.

Research output: Contribution to journalArticle

Hadad, S, Iwamoto, T, Jordan, L, Purdie, C, Bray, S, Baker, L, Jellema, G, Deharo, S, Hardie, DG, Pusztai, L, Moulder-Thompson, S, Dewar, JA & Thompson, AM 2011, 'Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial', Breast Cancer Research and Treatment, vol. 128, no. 3, pp. 783-794. https://doi.org/10.1007/s10549-011-1612-1
Hadad, Sirwan ; Iwamoto, Takayuki ; Jordan, Lee ; Purdie, Colin ; Bray, Susan ; Baker, Lee ; Jellema, Gera ; Deharo, Steve ; Hardie, D. Grahame ; Pusztai, Lajos ; Moulder-Thompson, Stacy ; Dewar, John A. ; Thompson, Alastair M. / Evidence for biological effects of metformin in operable breast cancer : A pre-operative, window-of-opportunity, randomized trial. In: Breast Cancer Research and Treatment. 2011 ; Vol. 128, No. 3. pp. 783-794.
@article{fae45da7108e4b36bda6bb12effa0260,
title = "Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial",
abstract = "Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot cohort of eight patients had core biopsy of the cancer at presentation, a week later (without treatment; internal control), then following metformin 500-mg o.d. for 1 week increased to 1-g b.d. for a further week continued to surgery. A further 47 patients had core biopsy at diagnosis were randomized to metformin (the same dose regimen) or no drug, and 2 weeks later had core biopsy at surgery. Ki67 immunohistochemistry, transcriptome analysis on formalin-fixed paraffin-embedded cores and serum insulin determination were performed blinded to treatment. Seven patients (7/32, 21.9{\%}) receiving metformin withdrew because of gastrointestinal upset. The mean percentage of cells staining for Ki67 fell significantly following metformin treatment in both the pilot cohort (P = 0.041, paired t-test) and in the metformin arm (P = 0.027, Wilcoxon rank test) but was unchanged in the internal control or metformin control arms. Messenger RNA expression was significantly downregulated by metformin for PDE3B (phosphodiesterase 3B, cGMP-inhibited; a critical regulator of cAMP levels that affect activation of AMP-activated protein kinase, AMPK), confirmed by immunohistochemistry, SSR3, TP53 and CCDC14. By ingenuity pathway analysis, the tumour necrosis factor receptor 1 (TNFR1) signaling pathway was most affected by metformin: TGFB and MEKK were upregulated and cdc42 downregulated; mTOR and AMPK pathways were also affected. Gene set analysis additionally revealed that p53, BRCA1 and cell cycle pathways also had reduced expression following metformin. Mean serum insulin remained stable in patients receiving metformin but rose in control patients. This trial presents biomarker evidence for anti-proliferative effects of metformin in women with breast cancer and provides support for therapeutic trials of metformin.",
keywords = "Breast cancer, Clinical trial, ki67, Metformin, Transcriptome analyses",
author = "Sirwan Hadad and Takayuki Iwamoto and Lee Jordan and Colin Purdie and Susan Bray and Lee Baker and Gera Jellema and Steve Deharo and Hardie, {D. Grahame} and Lajos Pusztai and Stacy Moulder-Thompson and Dewar, {John A.} and Thompson, {Alastair M.}",
year = "2011",
month = "8",
doi = "10.1007/s10549-011-1612-1",
language = "English",
volume = "128",
pages = "783--794",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Evidence for biological effects of metformin in operable breast cancer

T2 - A pre-operative, window-of-opportunity, randomized trial

AU - Hadad, Sirwan

AU - Iwamoto, Takayuki

AU - Jordan, Lee

AU - Purdie, Colin

AU - Bray, Susan

AU - Baker, Lee

AU - Jellema, Gera

AU - Deharo, Steve

AU - Hardie, D. Grahame

AU - Pusztai, Lajos

AU - Moulder-Thompson, Stacy

AU - Dewar, John A.

AU - Thompson, Alastair M.

PY - 2011/8

Y1 - 2011/8

N2 - Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot cohort of eight patients had core biopsy of the cancer at presentation, a week later (without treatment; internal control), then following metformin 500-mg o.d. for 1 week increased to 1-g b.d. for a further week continued to surgery. A further 47 patients had core biopsy at diagnosis were randomized to metformin (the same dose regimen) or no drug, and 2 weeks later had core biopsy at surgery. Ki67 immunohistochemistry, transcriptome analysis on formalin-fixed paraffin-embedded cores and serum insulin determination were performed blinded to treatment. Seven patients (7/32, 21.9%) receiving metformin withdrew because of gastrointestinal upset. The mean percentage of cells staining for Ki67 fell significantly following metformin treatment in both the pilot cohort (P = 0.041, paired t-test) and in the metformin arm (P = 0.027, Wilcoxon rank test) but was unchanged in the internal control or metformin control arms. Messenger RNA expression was significantly downregulated by metformin for PDE3B (phosphodiesterase 3B, cGMP-inhibited; a critical regulator of cAMP levels that affect activation of AMP-activated protein kinase, AMPK), confirmed by immunohistochemistry, SSR3, TP53 and CCDC14. By ingenuity pathway analysis, the tumour necrosis factor receptor 1 (TNFR1) signaling pathway was most affected by metformin: TGFB and MEKK were upregulated and cdc42 downregulated; mTOR and AMPK pathways were also affected. Gene set analysis additionally revealed that p53, BRCA1 and cell cycle pathways also had reduced expression following metformin. Mean serum insulin remained stable in patients receiving metformin but rose in control patients. This trial presents biomarker evidence for anti-proliferative effects of metformin in women with breast cancer and provides support for therapeutic trials of metformin.

AB - Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot cohort of eight patients had core biopsy of the cancer at presentation, a week later (without treatment; internal control), then following metformin 500-mg o.d. for 1 week increased to 1-g b.d. for a further week continued to surgery. A further 47 patients had core biopsy at diagnosis were randomized to metformin (the same dose regimen) or no drug, and 2 weeks later had core biopsy at surgery. Ki67 immunohistochemistry, transcriptome analysis on formalin-fixed paraffin-embedded cores and serum insulin determination were performed blinded to treatment. Seven patients (7/32, 21.9%) receiving metformin withdrew because of gastrointestinal upset. The mean percentage of cells staining for Ki67 fell significantly following metformin treatment in both the pilot cohort (P = 0.041, paired t-test) and in the metformin arm (P = 0.027, Wilcoxon rank test) but was unchanged in the internal control or metformin control arms. Messenger RNA expression was significantly downregulated by metformin for PDE3B (phosphodiesterase 3B, cGMP-inhibited; a critical regulator of cAMP levels that affect activation of AMP-activated protein kinase, AMPK), confirmed by immunohistochemistry, SSR3, TP53 and CCDC14. By ingenuity pathway analysis, the tumour necrosis factor receptor 1 (TNFR1) signaling pathway was most affected by metformin: TGFB and MEKK were upregulated and cdc42 downregulated; mTOR and AMPK pathways were also affected. Gene set analysis additionally revealed that p53, BRCA1 and cell cycle pathways also had reduced expression following metformin. Mean serum insulin remained stable in patients receiving metformin but rose in control patients. This trial presents biomarker evidence for anti-proliferative effects of metformin in women with breast cancer and provides support for therapeutic trials of metformin.

KW - Breast cancer

KW - Clinical trial

KW - ki67

KW - Metformin

KW - Transcriptome analyses

UR - http://www.scopus.com/inward/record.url?scp=79960845901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960845901&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1612-1

DO - 10.1007/s10549-011-1612-1

M3 - Article

C2 - 21655990

AN - SCOPUS:79960845901

VL - 128

SP - 783

EP - 794

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -